Memorial Sloan Kettering Posts $339 Million Operating Income
The cancer center's nine-month results through September 2026 reverse a prior-year operating loss.
Updated on Nov. 17, 2026 in Healthcare

Memorial Sloan Kettering Cancer Center reported $339.1 million in operating income through the third quarter of 2026, a 4.9% operating margin, compared with an operating loss of $174.9 million in the same period of 2025. Total operating revenue rose to $7 billion from $6.2 billion.
Why it matters
The swing from loss to profit reflects both higher patient volume and one-time gains, so the underlying margin is narrower than the headline figure suggests. For New York City, the results signal the financial health of a major local provider of specialized cancer care.
Total operating expenses rose to $6.6 billion from $6.4 billion, and excluding $169.5 million in prior-year Epic EHR go-live costs, expenses increased $409.8 million. Revenue growth included $57.3 million in COVID-19 relief funding and $35.9 million in settlement payments, and the filing does not indicate how much of that support will recur.
The players
Memorial Sloan Kettering Cancer Center
A New York City-based nonprofit cancer hospital and research institution that is among the best-known specialized cancer centers in the United States.
The details
Hospital care and services revenue reached $5.9 billion, up from $5.2 billion, while expense growth was driven mainly by personnel costs and higher pharmaceutical spending. Clinic visits totaled 587,062, up from 560,300, and telemedicine visits reached 282,260, up from 239,707.
Timeline
February 2025: Epic EHR go-live incurred $169.5 million in incremental expenses.
September 30, 2025: The prior-year nine-month period closed with a $174.9 million operating loss.
September 30, 2026: The nine-month period closed with $339.1 million in operating income.
November 13, 2026: The financial report covering third-quarter 2026 results was released.
Market Landscape
The turnaround places Memorial Sloan Kettering's finances against a backdrop of rising patient volumes and a higher case mix index of 2.71, up from 2.57, which signals more complex cases. That combination positions the center to compete on specialized oncology care rather than volume alone.
For patients, the results indicate that the center's expanded telemedicine capacity, with 282,260 visits through September, is now a substantial share of its outpatient care. The filing does not indicate whether these operating gains will change patient out-of-pocket costs or appointment availability.
The takeaway
Strong top-line growth does not always mean the core business has improved, so readers should look beyond headline profit figures to one-time items. Tracking how a hospital's operating margin holds once settlements and relief funding end offers a clearer picture of its long-term stability.
Further reading
For more on hospital finances, explore Healthcare coverage across the city's major medical centers.






